Advertisement

Psychopharmacology

, Volume 236, Issue 9, pp 2761–2771 | Cite as

Protective effect of potassium 2-(l-hydroxypentyl)-benzoate on hippocampal neurons, synapses and dystrophic axons in APP/PS1 mice

  • Longjian Huang
  • Yong Zhang
  • Yuchen Peng
  • Zirun Zhao
  • Yujun Zhou
  • Xiaoliang WangEmail author
  • Ying PengEmail author
Original Investigation

Abstract

Rationale

As the hub of memory and space, hippocampus is very sensitive to a wide variety of injuries and is one of the earliest brain structures to develop neurodegenerative changes in AD. Previous research has showed a protective effect of potassium 2-(l-hydroxypentyl)-benzoate (PHPB) on cognitive deficits in animal models of AD. However, it is unclear whether this protective effect is associated with hippocampal alterations.

Objectives

The present study was conducted to evaluate the protective effect of PHPB on hippocampal neurodegenerative changes in middle-aged APP/PS1 mice.

Methods

Ten-month-old male APP/PS1 transgenic mice and age-matched wild-type mice were randomly divided into three groups. PHPB-treated APP/PS1 group received 30 mg/kg PHPB by oral gavage once daily for 12 weeks. Wild-type group and APP/PS1 group received the same volume of water alone. Twelve weeks later, mice (13-month-old) were tested for in vivo 1H-MRS examination and then sacrificed for subsequent biochemical and pathological examinations using transmission electron microscopy, Golgi staining, immunohistochemistry, and western blotting.

Results

We found that PHPB treatment significantly improved the micromorphology of hippocampal neurons and subcellular organelles, ameliorated synapse loss and presynaptic axonal dystrophy, increased hippocampal dendritic spine density and dendritic complexity, enhanced the expression of hippocampal synapse-associated proteins, and improved hippocampal metabolism in middle-aged APP/PS1 mice.

Conclusions

Our study showed for the first time the protective effect of PHPB on hippocampal neurons, synapses, and dystrophic axons in APP/PS1 mice, which to some extent revealed the possible mechanism for its ability to improve cognition in animal models of AD.

Keywords

Alzheimer’s disease Potassium 2-(l-hydroxypentyl)-benzoate Hippocampal Synapse Dystrophic axon APP/PS1 mice 

Notes

Funding information

This project was supported by the grants from National Natural Sciences Foundation of China (No.81473200 and 81673420), CAMS Innovation Fund for Medical Sciences (No.2017-I2M-2-004), and the National Science and Technology Major Special Project on Major New Drug Innovation of China (2018ZX09711001-003-005, 2018ZX09711001-003-009).

Compliance with ethical standards

All experiments were approved and performed in accordance with the institutional guidelines of the Experimental Animal Center of the Chinese Academy of Medical Science, Beijing, China (No.00005668).

Conflict of interest

The author declares that there is no conflict of interest.

References

  1. Alpar A, Ueberham U, Bruckner MK, Seeger G, Arendt T, Gartner U (2006) Different dendrite and dendritic spine alterations in basal and apical arbors in mutant human amyloid precursor protein transgenic mice. Brain Res 1099:189–198CrossRefGoogle Scholar
  2. Amaral DG, Witter MP (1989) The three-dimensional organization of the hippocampal formation: a review of anatomical data. Neuroscience 31:571–591CrossRefGoogle Scholar
  3. Antequera D, Bolos M, Spuch C, Pascual C, Ferrer I, Fernandez-Bachiller MI, Rodríguez-Franco MI, Carro E (2012) Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on Abeta accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol Dis 46:682–691CrossRefGoogle Scholar
  4. Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 42:1681–1688CrossRefGoogle Scholar
  5. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31–39CrossRefGoogle Scholar
  6. Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR (1996) Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol 25:821–828CrossRefGoogle Scholar
  7. Coggeshall RE, Lekan HA (1996) Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 364:6–15CrossRefGoogle Scholar
  8. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology 38:1682–1687CrossRefGoogle Scholar
  9. Dayan AD (1970) Quantitative histological studies on the aged human brain. I. Senile plaques and neurofibrillary tangles in “normal” patients. Acta Neuropathol 16:85–94CrossRefGoogle Scholar
  10. Engelhardt E, Moreira DM, Laks J, Marinho VM, Rozenthal M, Oliveira AC Jr (2001) Alzheimer’s disease and magnetic resonance spectroscopy of the hippocampus. Arq Neuropsiquiatr 59:865–870CrossRefGoogle Scholar
  11. Franko E, Joly O (2013) Evaluating Alzheimer’s disease progression using rate of regional hippocampal atrophy. PLoS One 8:e71354CrossRefGoogle Scholar
  12. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83:4913–4917CrossRefGoogle Scholar
  13. Hattori N, Abe K, Sakoda S, Sawada T (2002) Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer’s disease. Neuroreport 13:183–186CrossRefGoogle Scholar
  14. Henriksen O (1995) In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed 8:139–148CrossRefGoogle Scholar
  15. Herminghaus S, Frölich L, Gorriz C, Pilatus U, Dierks T, Wittsack HJ, Lanfermann H, Maurer K, Zanella FE (2003) Brain metabolism in Alzheimer disease and vascular dementia assessed by in vivo proton magnetic resonance spectroscopy. Psychiatry Res 123:183–190CrossRefGoogle Scholar
  16. Hu WY, He ZY, Yang LJ, Zhang M, Xing D, Xiao ZC (2015) The Ca(2+) channel inhibitor 2-APB reverses beta-amyloid-induced LTP deficit in hippocampus by blocking BAX and caspase-3 hyperactivation. Br J Pharmacol 172:2273–2285CrossRefGoogle Scholar
  17. Hunt CA, Schenker LJ, Kennedy MB (1996) PSD-95 is associated with the postsynaptic density and not with the presynaptic membrane at forebrain synapses. J Neurosci 16:1380–1388CrossRefGoogle Scholar
  18. Jack CR Jr et al (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489CrossRefGoogle Scholar
  19. Jack CR Jr et al (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62:591–600CrossRefGoogle Scholar
  20. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165CrossRefGoogle Scholar
  21. Jones RS, Waldman AD (2004) 1H-MRS evaluation of metabolism in Alzheimer’s disease and vascular dementia. Neurol Res 26:488–495CrossRefGoogle Scholar
  22. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 19:5720–5728CrossRefGoogle Scholar
  23. Kennedy MB (1997) The postsynaptic density at glutamatergic synapses. Trends Neurosci 20:264–268CrossRefGoogle Scholar
  24. Kim E, Sheng M (2009) The postsynaptic density. Curr Biol 19:R723–R724CrossRefGoogle Scholar
  25. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA (1991) An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci U S A 88:7247–7251CrossRefGoogle Scholar
  26. Li PP, Wang WP, Liu ZH, Xu SF, Lu WW, Wang L, Wang XL (2014) Potassium 2-(1-hydroxypentyl)-benzoate promotes long-term potentiation in Abeta1-42-injected rats and APP/PS1 transgenic mice. Acta Pharmacol Sin 35:869–878CrossRefGoogle Scholar
  27. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR, Ugurbil K, Garwood M (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A 102:11906–11910CrossRefGoogle Scholar
  28. Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML (2004) Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 33:377–387CrossRefGoogle Scholar
  29. Nixon RA (2007) Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci 120:4081–4091CrossRefGoogle Scholar
  30. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM (2005) Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 64:113–122CrossRefGoogle Scholar
  31. Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, Lindberg M (2008) Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol Aging 29:1423–1433CrossRefGoogle Scholar
  32. Peng Y, Xu S, Chen G, Wang L, Feng Y, Wang X (2007) L-3-n-butylphthalide improves cognitive impairment induced by chronic cerebral hypoperfusion in rats. J Pharmacol Exp Ther 321:902–910CrossRefGoogle Scholar
  33. Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng Y, Wang X (2008) L-3-n-butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells. Neurosci Lett 434:224–229CrossRefGoogle Scholar
  34. Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA (2010) L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer’s disease. J Neurosci 30:8180–8189CrossRefGoogle Scholar
  35. Peng Y, Hu Y, Xu S, Li P, Li J, Lu L, Yang H, Feng N, Wang L, Wang X (2012) L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AbetaPP/PS1-Alzheimer's transgenic mice. J Alzheimers Dis 29:379–391CrossRefGoogle Scholar
  36. Peng Y, Hu Y, Xu S, Rong X, Li J, Li P, Wang L, Yang J, Wang X (2014) Potassium 2-(1-hydroxypentyl)-benzoate improves memory deficits and attenuates amyloid and tau pathologies in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 350:361–374CrossRefGoogle Scholar
  37. Rochefort NL, Konnerth A (2012) Dendritic spines: from structure to in vivo function. EMBO Rep 13:699–708CrossRefGoogle Scholar
  38. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, Semple J, Doddrell DM (1999) A 1H MRS study of probable Alzheimer’s disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17:291–299CrossRefGoogle Scholar
  39. Scheff SW, Price DA (2003) Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies. Neurobiol Aging 24:1029–1046CrossRefGoogle Scholar
  40. Scheff SW, Price DA, Schmitt FA, Mufson EJ (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 27:1372–1384CrossRefGoogle Scholar
  41. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer’s disease. Lancet 388:505–517CrossRefGoogle Scholar
  42. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791CrossRefGoogle Scholar
  43. Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA (2011) A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci 12:585–601CrossRefGoogle Scholar
  44. Spires-Jones T, Knafo S (2012) Spines, plasticity, and cognition in Alzheimer’s model mice. Neural Plast 2012:319836CrossRefGoogle Scholar
  45. Sun XC, Li L, Zhang M, Li WB, Li QJ, Zhao L (2012) Division of CA1, CA3 and DG regions of the hippocampus of Wistar rat. Zhongguo Ying Yong Sheng Li Xue Za Zhi 28:189–192Google Scholar
  46. Ten Kate M et al (2017) Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging 52:167–182 e161 CrossRefGoogle Scholar
  47. Tu S, Okamoto S, Lipton SA, Xu H (2014) Oligomeric Abeta-induced synaptic dysfunction in Alzheimer's disease. Mol Neurodegener 9:48CrossRefGoogle Scholar
  48. Unger MS, Marschallinger J, Kaindl J, Höfling C, Rossner S, Heneka MT, van der Linden A, Aigner L (2016) Early changes in hippocampal neurogenesis in transgenic mouse models for Alzheimer’s disease. Mol Neurobiol 53:5796–5806CrossRefGoogle Scholar
  49. van Spronsen M, Hoogenraad CC (2010) Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep 10:207–214CrossRefGoogle Scholar
  50. Wang H, Tan L, Wang HF, Liu Y, Yin RH, Wang WY, Chang XL, Jiang T, Yu JT (2015) Magnetic resonance spectroscopy in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis 46:1049–1070CrossRefGoogle Scholar
  51. Zhang Y, Wang L, Li J, Wang XL (2006) 2-(1-Hydroxypentyl)-benzoate increases cerebral blood flow and reduces infarct volume in rats model of transient focal cerebral ischemia. J Pharmacol Exp Ther 317:973–979CrossRefGoogle Scholar
  52. Zhao W, Xu S, Peng Y, Ji X, Cao D, Li J, Liu B, Shi Q, Wang L, Wang X (2013) Potassium 2-(1-hydroxypentyl)-benzoate improves learning and memory deficits in chronic cerebral hypoperfused rats. Neurosci Lett 541:155–160CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia MedicaChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Trinity College of Arts and SciencesDuke UniversityDurhamUSA
  3. 3.Pharmacology Department, Institute of Materia MedicaChinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina

Personalised recommendations